Stomach Cancer Didn't Respond to Rx dailyRx This new study — the GRANITE-1 (First Gastric Antitumor Trial With Everolimus) — looked at the efficacy and safety of everolimus in advanced stomach cancer patients whose disease had progressed despite one or two lines of chemotherapy. A total of 656 ... |
